Using establishment, divestitures, mergers, acquisitions and alliances to expand and consolidate businesses
First written in FY2016. 11 of 20 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 9 of 30 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「September 2026: 100% of the shares of DVx Inc. (Minato-ku, Tokyo; consolidated subsidiary) were acquired through a share exchange to expand the sales area and market base of the medical equipment business.」
As a means of corporate reorganisation, a specific management integration was carried out by acquiring 100% of the shares of DVx Inc. through a share exchange and making it a consolidated subsidiary. - FY2025-H1AdvancedAnnual report
「THAI OLBA Healthcare Co.,Ltd. has become consolidated from the current interim consolidated accounting period because its materiality has increased.」
As a specific development in business expansion and alliances, the Thai joint venture THAI OLBA Healthcare Co., Ltd. became subject to consolidation because its importance increased. - FY2024RestatedAnnual report
「The Group may continue to use various methods, including establishing or selling affiliated companies, mergers, demergers, acquisitions, and business alliances, when expanding, consolidating, or reorganizing its businesses.」
The possibility of using establishment, sale, merger, demerger, acquisition and business alliances for business expansion and consolidation, together with the associated effects of expenses and impairment losses, continues to be treated as a risk. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The disclosure states that there were no material changes in the risks associated with business expansion and consolidation during the second quarter. - FY2023-Q3AdvancedAnnual report
「In addition, for the purpose of selling medical equipment mainly in Thailand, we entered into a JOINT BUSINESS AGREEMENT on 26 January 2023 with Thai individual shareholders concerning a joint investment in and operation of THAI OLBA Healthcare Co., Ltd. (formerly Medical Device Innovation Co., Ltd.), and commenced the joint venture business.」
As a means of business expansion, a joint investment with Thai individual shareholders in a joint venture for the sale of medical equipment in Thailand and an operating agreement were concluded, and the joint venture business was commenced. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The disclosure states that there were no material changes in the risks associated with business expansion and consolidation during the second quarter. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The disclosure states that there were no material changes in the risks associated with business expansion and consolidation during the first quarter. - FY2022AdvancedAnnual report
「June 2022: To expand the market base for the clinic business, the Company additionally acquired shares in Kawanishi Barkmed Co., Ltd. (consolidated subsidiary) and made it a wholly owned subsidiary.」
Additional shares in カワニシバークメド were acquired to expand the market base of the business serving clinics, making it a wholly owned subsidiary. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The disclosure states that there were no material changes in the risks associated with business expansion and consolidation during the quarter. - FY2020RestatedAnnual report
「The company was established on 1 July 2019 to strengthen its business serving clinics.」
As a specific example of business expansion and alliances, the full-year disclosure includes the establishment of カワニシバークメド to strengthen its business serving clinics. - FY2020-Q3RestatedAnnual report
「As 株式会社カワニシバークメド was newly established from the first quarter of the consolidated fiscal year, it has been included in the scope of application of the equity method.」
The establishment of 株式会社カワニシバークメド and its addition as an equity-method affiliate continue to be disclosed. - FY2020-Q2RestatedAnnual report
「As 株式会社カワニシバークメド was newly established from the first quarter of the consolidated fiscal year, it has been included in the scope of application of the equity method.」
The continued disclosure states that 株式会社カワニシバークメド was newly established and made an equity-method affiliate. - FY2020-Q1AdvancedAnnual report
「Because Kawanishi Barkmed Co., Ltd. was newly established from the current first quarter of the consolidated fiscal year, it has been included in the scope of application of the equity method.」
As a specific business expansion and alliance initiative, 株式会社カワニシバークメド was newly established and made an equity-method affiliate. - FY2019RestatedAnnual report
「The Group may continue to use various methods, including establishing or selling affiliated companies, mergers, demergers, acquisitions, and business alliances, when expanding, consolidating, or reorganizing its businesses.」
The possibility of using establishment, sale, merger, demerger, acquisition and business alliances for business expansion and consolidation, together with the associated effects of expenses and impairment losses, continues to be treated as a risk. - FY2018RestatedAnnual report
「March 2018: 株式会社オオタメディカル (consolidated subsidiary) was liquidated to improve management efficiency.」
The liquidation of オオタメディカル has been reflected as a specific example of corporate reorganisation and consolidation in the full-year corporate history and changes to the scope of consolidation. - FY2018-Q3AdvancedAnnual report
「In addition, regarding changes involving major affiliates, Ohta Medical Co., Ltd., a consolidated subsidiary of the Company that belonged to the Medical Equipment business, was excluded from the scope of consolidation from the current third quarter of the consolidated fiscal year because its liquidation was completed on 30 March 2018.」
Against the general disclosure of possible corporate reorganisations and consolidations, specific reorganisation results were presented: the completion of the liquidation of 株式会社オオタメディカル and its exclusion from the scope of consolidation. - FY2017RestatedAnnual report
「株式会社エクソーラメディカル, which was an unconsolidated subsidiary in the previous consolidated fiscal year, has been included in the scope of consolidation from the current consolidated fiscal year because its importance has increased. In addition, 高塚ライフサイエンス㈱, which had been a consolidated subsidiary, ceased to exist as a result of an absorption-type merger on 1 January 2017, with ㈱カワニシ as the surviving company, and has therefore been excluded from the scope of consolidation from the current consolidated fiscal year.」
The absorption-type merger of 高塚ライフサイエンス株式会社 and the addition of エクソーラメディカル to the scope of consolidation have been reflected as full-year corporate reorganisation results. - FY2017-Q2AdvancedAnnual report
「Taka-tsuka Life Science Co., Ltd., which belonged to the Life Science business in the second quarter of the previous consolidated fiscal year, merged in January 2017, with Kawanishi Co., Ltd., which belongs to the Medical Equipment business, as the surviving company.」
The merger of 高塚ライフサイエンス株式会社 and 株式会社カワニシ, decided in the previous quarter, was completed. - FY2017-Q1AdvancedAnnual report
「Takamatsu Life Science Co., Ltd., which belonged to the Life Science Business in the first quarter of the previous fiscal year, is scheduled to merge with 株式会社カワニシ, which will be the surviving company and belongs to the Medical Equipment Business, in January 2017.」
The disclosure moved from the possibility of conventional general business consolidation methods to a specific plan to merge 高塚ライフサイエンス株式会社 and 株式会社カワニシ. - FY2016First statedAnnual report
「The Group may continue to use various methods, including establishing or selling affiliated companies, mergers, demergers, acquisitions, and business alliances, when expanding, consolidating, or reorganizing its businesses.」
The company indicates that it may use multiple forms of corporate restructuring to expand, consolidate and reorganize its businesses, while identifying the possibility that related costs and other factors could affect business performance and financial position as a risk.